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ESTABLISHING A CLINICALLY RELEVENT MOUSE OF HUMAN AML TO 
TEST NOVEL TRANSMETHYLATION INHIBITORS 
Aditya Barve 
August 18, 2016 
Acute myeloid leukemia (AML) is a highly heterogeneous clonal disorder 
characterized by an accumulation of malignant immature myeloid progenitors in 
the bone marrow (BM) that hinder normal hematopoiesis. Patient AML exhibits a 
dramatic heterogeneity in terms of cytogenetics, disease morphology, and 
associated prognoses and/or chemotherapeutic sensitivity. Thus it becomes 
clearly evident that the investigation of novel therapeutics for AML will require 
model systems that are capable of recapitulating this stark heterogeneity in a 
patient specific manner. Furthermore, it is now understood that the surrounding 
bone marrow (BM) microenvironment and supporting cells play a critical role in 
leukemic progression as well as providing a chemotherapy protected sanctuary 
for residual disease. Therefore, the focus of this study was the establishment and 
development of a more clinically relevant mouse xenograft model of patient 
derived AML that not only recapitulates patient disease but also simulates the 
clinical standard of care induction therapy. The crux of our model system was the 
NRGS mouse, which were not only capable of reliable high rates of engraftment 
of established cell lines and patient derived AML cells, but also expresses three 
human myeloid cytokines (IL-3, GM-CSF, SF). Additionally these mice were able
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 to tolerate aggressive induction therapy at doses similar to those administered to 
patients, and therapy was efficacious in prolonging the survival of mice engrafted 
with patient AML. Such model systems that can simulate patient specific AML 
along with the standard of care therapy, will be essential for the successful 
investigation of novel, translational therapeutics. 
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 Acute myeloid leukemia (AML) is a highly heterogeneous cancer 
characterized by an accumulation of malignant immature myeloid progenitors in 
the bone marrow (BM), peripheral blood, and rarely the central nervous system. 
These malignant cells proliferate rapidly and accumulate in the BM disrupting 
normal hematopoiesis. Recent studies have shown that these cells arise through 
the clonal expansion of myeloid committed hematopoietic stem cells (HSC) that 
have accumulated abnormal genetic alterations with age, resulting in a block in 
normal hematopoietic differentiation and aberrant proliferation. Thus AML 
exhibits a dramatic heterogeneity in terms of cytogenetics, disease morphology, 
patient prognosis and exhibits and an even more pronounced molecular diversity. 
 AML is the most predominant leukemia in older patients, and the dramatic 
increase in modern life expectancy is causing the incidence to skyrocket. The 
incidence of new cases of AML has risen by 2.2% every year for the last 15 
years. There will be an estimated 21,000 new cases of AML diagnosed this year 
in the U.S.  Luckily, modern chemotherapy allows approximately 60-70% of 
patients to achieve CR, but unfortunately the overall 5-year survival remains poor 
at only 26%, due largely to relapse.1 The extreme heterogeneity of disease 
genetics and morphology presents a unique challenge for oncologists, as each 
case of AML is unique with its own associated prognosis and chemotherapeutic
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 sensitivity. Therefore novel, patient tailored therapies and/or treatment 
paradigms that are more efficacious, specific toatient cytogenetics, and better 
tolerated by elderly patients, must be developed in conjunction with standard of 
care therapy.2 
 As mentioned previously the cytogenetic heterogeneity of AML has long 
been recognized as the most important prognostic marker, as AMLs of varied 
etiologies have extremely different morphology and drug sensitivity. Accordingly, 
several systems of classification have been developed using differences in 
genetics, cellular morphology, and immune phenotype. During the 1970s AML 
was classified according to the French-American-British classification system 
which relies mainly on morphology and immunological phenotype, along with 
cytochemical criteria to define eight major subtypes (FAB M0 to M7).3 The 
fundamental basis of this classification system was established by light 
microscopy examination of malignant cells as well as some limited cytogenetics 
characterizing recurrent genetic abnormalities. The numerical hierarchy of this 
classification system corresponds with both the degree of maturity (lowest being 
most stem) as well as the progenitor cell type from which the leukemia 
developed.  
 While groundbreaking in its novelty and recognition of morphology and 
some cytogenetics as key determining factors in overall prognosis, this system 
was found to be lacking in some instances. FAB classification worked well in 
instances where observed genetic lesions directly induced observed cellular 
morphology and cytochemical signaling. For example in acute promyelocytic 
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leukemia (APL) or acute myelomonocytic leukemia with abnormal eosinophils 
(M4Eo) the morphological characteristics directly predict the genetic 
abnormalities making these classifications very accurately.4 However as research 
progressed it became more and more evident that morphology/cytochemistry did 
not always correlate with or predict observed genetic abnormalities, and 
differences in genetic abnormalities were frequently observed even in patients 
with the same proposed sub-type of AML. Additionally there are many cases in 
which there is absolutely no correlation between observed genetic defects and 
morphology, highlighting the fact that genetic profiling of AML provides a much 
more accurate system of classification and prognostic prediction. Thus, the FAB 
system was the first to recognize the immense morphological heterogeneity of 
AML and its value as a criteria for classification, but does not accurately convey 
the genetic diversity and associated clinical outcomes of the disease.    
 In 2001 the World Health Organization developed an alternate system of 
classification that is based on the central concept that the subgroups of AML are 
actually distinct diseases through correlation of genetic, morphologic, and clinical 
data. This new system of classification is significantly different from the FAB 
system as it utilizes a lower blast threshold for AML diagnosis and perhaps most 
significantly it defines cases of AML into unique subgroups based on biological, 
clinical, and genetic characteristics. The WHO classification system was updated 
in 2008 to its current format and defines seven major AML subtypes: 1.) AML 
with recurrent genetic abnormalities, 2.) AML with myelodysplatic related 
changes, 3.) therapy-related myeloid neoplasms, 4.) Myeloid sarcoma, 5.) 
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Myeloid proliferations related to Down Syndrome, 6.) Blastic plasmacytoid 
dendritic cell neoplasm, and 7.) AML otherwise not categorized (very similar to 
the FAB system with some additions).4 Each major subgroup is divided into 
specific subcategories based on commonly observed recurrent genetic 
abnormalities, detailed karyotype analyses, and molecular abnormalities, thus 
providing a much better representation of the vastly different genetic landscape 
of AML even in morphologically similar cases. It becomes clearly evident that the 
WHO system of classification is far superior to the FAB system in terms of scope 
and descriptiveness, making it the chosen methodology for classification of AML 
in modern medicine.  
 Current chemotherapeutic treatment of AML is broken into two distinct 
phases, the first being induction therapy whose aim is to reduce the overall 
leukemic blast burden and induce remission. Unfortunately, intensive induction 
therapy has remained virtually unchanged since the 1970s and is effective in 
inducing CR in 60-70% of patients who are able to tolerate the therapy. Sadly, 
greater than 45% of patients achieving CR have a less than three year overall 
survival due to relapse and refractory disease. The standard of care induction 
therapy for young adults and healthy elderly patients is an intensive anthracycline 
and cytarabine regimen. Also commonly referred to as “7+3”, induction therapy 
utilizes a cytotoxic anthracycline like daunorubicin, idarubicin, or doxorubicin (60 
or 90 mg/m2) administered the first three days along with continuous intravenous 
infusion of cytarabine (Ara-C, 100mg/m2) for seven days. As previously stated 
the goal of induction therapy is to induce morphological remission which is 
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quantified as less than 5% blasts in the bone aspirate sample with marrow 
spicules and with a count of greater than 200 nucleated cells (must lack Auer 
rods and/or extramedullary disease). There must also be a platelet count greater 
than or equal to 100,000 cells/ml of blood and an absolute neutrophil count that 
is greater than 1000 cells/ul.5-7  
 Consolidation therapy, the second phase of current standard of care AML 
therapy, aims to prevent relapse and reduce the minimal residual disease (MRD) 
or leukemic blasts and leukemic founder cells protected from cytotoxic drug 
exposure in the BM microenvironment. These cells are the causative agents of 
refractory relapse, the major cause of patient mortality, and no current approved 
treatment regimens exist for relapsed AML. Oncologists have two options for 
consolidation therapy: 1.) Additional chemotherapy with intermediate dose 
cytarabine (1.5g/m2) twice daily on days 1, 3, and 5 in 3-4 cycles or 2.) HSC 
transplantation (HSCT).5 These strategies can be used at the clinician’s 
discretion alone or in combination depending on the patient’s subtype of 
leukemia, ability to tolerate chemotherapy, and availability of compatible donors. 
Chemotherapeutic consolidation therapy (3-4 cycles) alone has been shown to 
effectively improve survival and lengthen remission in patients less than 60 years 
of age, leaving HSC transplant as a last resort in the result of relapse. 
Comparisons of high dose (3 g/m2) and intermediate dose (1.5 g/m2) cytarabine 
show equal benefit for patients under 60 years of age and therefore the 
intermediate dose became the standard of care, while the high dose regimen 
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showed greater efficacy in patients with CBF AML [t(8:21); or inv(16)] or AML 
with mutated NPM1.8,9 
 In other prognostic groups allogenic stem cell transplantation remains the 
most effective long term therapy for AML after, with up to 60% of patients 
receiving transplant being cured. However numerous patients are deemed 
ineligible for transplant due to failure to achieve CR, co-morbidities, or lack of 
suitable donors. Initially age was thought to be the only determining factor in 
deciding whether or not to use HSCT, but new evidence conclusively shows that 
transplant success is dependent instead on active remission status and co-
morbidities. Also improvements in conditioning regimens, supportive care, and 
haplo-identical/cord grafts have allowed a much larger segment of the patient 
population to be eligible for HSCT. Still the risk of relapse remains significantly 
higher in patients treated with HSCT alone and many patients are unable to 
receive transplant.10,11    
          A special case exists for only patients who are suspected of having the 
APL subtype of AML, which is treated with all trans retinoic acid even before 
genetic analyses are completed and disease presence confirmed. This therapy is 
clinically approved, even pre-diagnosis, and potently induces granulocytic 
differentiation in malignant APL blasts inducing apoptosis, quiescence, and 
increased cytotoxic drug sensitivity. Induction therapy is initiated in combination 
with ATRA upon confirmation of disease, and the combination of induced 
differentiation and cytotoxic chemotherapy has produced ground breaking results 
in multiple clinical trials worldwide. Rates of CR were 80-90% and rates of long 
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term survival conservatively exceed 75% changing APL’s former grim prognosis 
into the most treatable form of AML. Considering AML is inherently different from 
other cancers in that AML blasts are essentially immature cells blocked in 
differentiation, novel therapies that force differentiation and maturation are highly 
attractive strategies for the treatment of AML as demonstrated by the success of 
ATRA in combination with induction therapy. Further study is required to develop 
new drugs that are capable of inducing differentiation in multiple or hopefully all 
types of AML, as demonstrated by the amazing improvement in survival and CR 
rates of APL treated with ATRA.12                             
 Chromosomal irregularities (deletions, tandem repeats, translocations 
etc.) are observed in the majority of all primary AML cases (approximately 52%) 
and have long been recognized as causative events that cause and promote 
leukemic progression.8 Each of these chromosomal abnormalities can be 
correlated with varied treatment outcomes, patient survival, and duration of 
remission making cytogenetic analysis of AML a critical factor in determining 
treatment options and how aggressively the leukemia is treated. For example, 
AMLs that have  t(8;21)(q22;q22), inv(16)(p13.1q22), or t(15;17)(q22;q12) have a 
universally better prognosis with prolonged survival time as compared to other 
irregularities like alterations involving chromosomes 5 and 7 (complex karyotype 
AML) or 11q23 are associated with much shorter survival and diminished 
chemotherapeutic sensitivity.13 Often times these genetic abnormalities result in 
the expression of characteristic abnormal fusion proteins (AML-ETO, PML-
RARA, MLL fusions, DEK-CAN, etc.) many of which have been directly linked to 
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the observed block in differentiation and stem like phenotype of AML cells. 
Interestingly, approximately 40-50% of all AML cases are actually cytogenetically 
normal (CN-AML) using conventional analysis,14 showing conclusively that AML 
associated genetic irregularities are not the only factor at play during the 
development of myeloid leukemia. Recent work is now starting to show that the 
presence or absence of specific mutations and/or altered regulation of gene 
expression can be used to further differentiate various types of AML (especially 
CN-AML) and possibly provide novel avenues of targeted therapy. This would 
allow treatment of AML in a patient specific manner, thereby greatly improving 
survival in patients harboring specific mutations or irregular patterns of gene 
expression regulation resulting molecular abnormalities.        
 Experts are now only starting to understand the effects of dysregulated 
patterns of gene expression and mutation status and how these effects mediate 
leukemogenisis.4,15,16 This is of special importance in people diagnosed with CN-
AML which appears normal according to karyotyping analysis, and lack the 
obvious genetic lesions found in other subtypes of AML. As such the prognostic 
value of cytogenetic analysis is limited in these patients, but with the advent of 
next-generation sequencing the genetic portrait of CN-AML has become much 
clearer. It is now understood that on average CN-AMLs have 13 mutations, five 
of which are recurrent “driver” mutations (directly causing leukemogenesis) and 
eight are recurrent random “passenger” mutations.15 These mutations result in 
molecular abnormalities in the proteins produced, and these abnormalities are 
now being identified as key mediators of AML pathogenesis, as well as valuable 
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prognostic markers accurately predicting clinical outcome, and as novel 
druggable targets for new therapeutic approaches. Several mutations have come 
to the forefront as they have extremely high relative frequency in AML, and the 
most significant will be discussed here in brief.  
 Nucleophosmin 1 mutations (NPM1) mutations are by far the most 
recurrent molecular abnormality observed in AML and can be found in 
approximately 25-30% of patients.17,18 Mutations in NPM1 result in expression of 
an aberrant protein that shows abnormal cellular localization in the cytoplasm 
instead of the nucleus and this expression greatly promotes myeloid proliferation 
and leukemogenesis.18,19 AMLs having these mutations generally present with a 
monocytic morphology with a generally favorable outcome in the absence of 
other mutations (namely FLT3 internal tandem deletions). This is perhaps the 
most clearly evident demonstration of the importance of deep-sequencing AML to 
examine potential molecular abnormalities as a way to guide therapy. AMLs with 
NPM1 mutations have been conclusively shown to have a greater sensitivity to 
standard of care induction chemotherapeutics and as such the overall survival is 
greatly increased in both old and young patients as compared to other molecular 
abnormalities.20 However NPM1 mutations are also associated with several other 
recurrent abnormalities like DNA methyltransferase 3A (DNMT3A), FLT3 internal 
duplications (FLT3-ITD), and isocitrate dehydrogenase mutations, most of which 
in conjunction with NPM1 mutations actually worsen the prognosis.21 
 Fms-Like Tyrosine kinase (FLT3) was first identified in 1991 as a crucial 
regulator of normal hematopoiesis and plays highly important roles in mediating 
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cell survival and proliferation during hematopoiesis.22,23 Internal tandem 
duplications (ITD) in region of the FLT3 gene coding for the juxta-membrane 
domain or second tyrosine kinase domain of this tyrosine kinase have been 
found in approximately 20% of all AML cases and 30-45% of CN-AML cases.24 
These mutations create constitutively activate FLT3 promoting aberrant 
proliferation in leukemic blasts.25 Thus patients with AML expressing FLT3-ITDs 
exhibit extreme leukocytosis and characteristic nuclear invagination, and these 
mutations are universally associated with poor prognosis, reduced survival and 
marked increase in risk of relapse. As expected the occurrence of these 
mutations in combination with other commonly recurring AML mutations 
(including those predicting better outcome) is correlated with diminished survival 
and increased rate of relapse. Interestingly, studies have also shown that non-
juxta membrane domain mutations are associated with a worse prognosis as 
compared to mutations occurring in this region, again showing the clinical 
significance of mutations resulting in molecular abnormalities as a predictive 
biomarker for patient outcome and to guide therapy.26                
 Mutations of the DNMT3 gene occur in a reasonable amount of AML 
cases (approximately 18-22% of all cases, 34% in CN-AML), the most common 
being missense mutations affecting arginine codon 822, while less common 
mutations in other codons have also been observed.21 These mutations have 
now been found to actually be pre-leukemic and arise very early in the evolution 
of the disease, but also persist even in times of CR. This finding is significant in 
that these mutations are perhaps the most common mutations involving proteins 
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that regulate gene expression in AML.27 DNMT3A is a de novo methylase that is 
capable of methylation of CpG dinucleotides in the promoter regions of target 
genes thereby mediating transcriptional silencing by blocking access of 
transcriptional machinery to these promoters. This form of regulation, which is 
independent of the genetic sequence, is known as epigenetic regulation and only 
very recently have methylation and other epigenetic mechanisms become 
recognized as relevant to leukemogenesis.28 Therefore it is logical that these 
mutations occur very early in leukemic development, and may even play a 
causative role in AML, by silencing genes required for maintenance of normal 
myeloid differentiation and hematopoiesis. Finally, the value of DNMT3A 
mutations as prognostic indicators remains hotly debated with some smaller 
studies finding a lowered overall survival (OS) and disease free survival (DFS) in 
patients expressing these mutations, while a much larger cohort study found no 
correlation between DNMT3A mutation status and clinical outcome.21,29  
 These three mutations have the highest relative frequency of recurrence in 
AML patients, but it is important to recognize that they only represent a small 
fraction of the vast array of genetic and molecular abnormalities found in AML. It 
becomes clearly evident that AML has a heterogeneity that is one of the most 
extreme in all known cancers, and these differences result in drastically different 
treatment modalities and patient prognoses. As such the development of novel 
targeted therapeutics and treatment paradigms requires in vivo model systems 
that are capable of faithfully recapitulating the extreme genetic and morphologic 
variability found in patient AMLs. Furthermore such systems must also be able to 
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replicate standard of care induction therapy, not only as a more relevant control 
(as compared to vehicle only), but also as a more clinically applicable way to test 
experimental therapeutics and their translational efficacy.  
 Animal models have been consistently shown to better predict the success 
of experimental therapeutics in clinical trials, and this holds especially true for the 
investigation of new drugs for AML, as a complex and highly dynamic interaction 
exists between heterogeneous populations of leukemic cells and the surrounding  
BM microenvironment.30 Current evidence supports the conclusion that specific 
niches within the BM microenvironment actually provide a protected sanctuary for 
specific subpopulations of leukemic cells capable of self-renewal and clonogenic 
proliferation, dubbed leukemic stem cells (LSCs). Seminal studies using early 
xenograft models were able to establish that only the most primitive fraction (Lin-
CD34+) of patient AML cells, and not the more mature blast population, were 
capable of transferring disease to primary and secondary NOD/SCID recipient 
mice.31,32 It becomes evident that a hierarchy similar to normal hematopoiesis 
exists in AML, with a small population of self-renewing LSCs giving rise to a large 
population of mature, clonally expanded blasts. LSCs are able to evade normal 
induction chemotherapy, due to a low rate of proliferation and protection 
conferred by the BM microenvironment, and are therefore thought to be the 
cause of the high rate of relapse and mortality associated with AML. Perhaps 
more alarming is the mounting data that these LSCs can actively induce changes 
in the BM microenvironment not only at the structural level but in cytokine 
production and genetic/epigenetic abnormalities within supporting BM stromal 
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cells.33,34 Co-culture experiments have shown that HSCs cultured on BM stroma 
collected from AML patients have a pronounced impairment in both self-renewal 
and survival capacity, while LSCs lose neither attribute on AML or normal 
stroma.  
 Thus LSCs induce changes to the BM microenvironment and supporting 
cells which favor LSC survival and maintenance while simultaneously 
compromising its ability to support and maintain normal HSC survival and 
differentiation. These interactions add another layer of complexity, additional to 
the dramatic heterogeneity of AML, which again must be accounted for in model 
systems that will ultimately be useful in the development of successful 
therapeutic paradigms that will truly translate to clinical care. Again in vivo animal 
studies remain the only reliable way to examine the highly complex interplay 
between leukemic populations (LSC and blast populations) and the protected BM 
niche, and by extension the pharmacological efficacy of novel therapeutics. 
Finally, in vivo methodologies have been shown to have significant advantages in 
success rates of experimental drugs as compared to in vitro techniques which 
often show success in the lab, but due to the lack of an accurate organ specific 
extracellular environment, cross talk between hormone or different cell types, 
differential metabolism, and site specific delivery often fail to show efficacy in 
clinical trials. This remains especially true for AML as effective novel therapeutics 
must be able to target the largely quiescent and protected LSC population 
residing in the bone marrow, or alternatively target the bone marrow 
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microenvironment to make it unfavorable for leukemic growth or promote normal 
hematopoiesis.                                 
 The development of the first immune deficient strains of mice in the 1960s 
overcame a major technical hurdle required to create such more clinically 
relevant xenograft mouse models which allow for the engraftment of human cells. 
Attempts are now even being made to replicate human cytokine signaling 
through transgenic mice that expressing human cytokines, thus starting to model 
the exquisitely complex role of cytokine signaling in leukemic and normal 
hematopoiesis. These “humanized” models, in which human cells can engraft 
and function have become revolutionary in the study of both normal and 
malignant human hematopoiesis, and will play a crucial role in the development 
of new therapeutics and treatment paradigms. 
 Highly immune deficient mice have become indispensable to the study of 
both normal and malignant human hematopoiesis, as these mice do not reject 
human xenografts and support the differentiation and continued growth of human 
cells. Discovered in 1962, nude or athymic mice were the first immune 
compromised mouse strain capable of accepting human cells and tissues and 
soon after severe combined immune deficiency (SCID) mice.35 SCID mice 
completely lack the ability to mount and sustain effective adaptive immune 
responses, due to an absence of functioning T and B lymphocytes, caused by a 
recessive mutation resulting in deficient activity of the enzyme; protein kinase, 
DNA activated, catalytic polypeptide (Prkdc). This enzyme is crucial in DNA 
damage repair as well as required for V(D)J recombination which explains how 
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this mutation disrupts the maturation and function of T and B lymphocytes. SCID 
mice were found to be far superior to nude mice in terms of engraftment of 
human tissues, and further refinement came with the development of non-obese 
diabetic (NOD)/SCID mice through the introduction of the Prdkcscid gene into an 
inbreeding NOD strain.36,37 These mice showed even greater rates of human cell 
engraftment as compared to SCID mice. Similarly, mice with that have a 
defective recombination activated gene (RAG, can be either Rag1/2null) also 
display a SCID phenotype and were crossed with NOD mice resulting in 
NOD/Rag1/2null mice also capable of reliable human tissue growth and 
engraftment.38,39 Numerous iterations of transgenic (NOD)/SCID mice capable of 
expressing various human cytokines were developed in an attempt to further 
improve rates of engraftment and promote true multilineage hematopoiesis, 
growth, and differentiation of human hematopoetic cells.40  
The early 2000s saw the advent of a series of immune deficient mice 
appropriate for the creation of truly “humanized” mouse models that showed not 
only high rates of engraftment, but also well-differentiated multilineage expansion 
and engraftment of human leukemia or HSCs. These mice were developed 
through the introduction of a mutant IL2ry gene into (NOD)/SCID mice through 
respective backcross mating, resulting in the generation of the two most widely 
used strains of immune deficient mice, NOG and NSG mice, which are 
(NOD)/SCID IL-2rynull and differ only in the location of the SCID mutation.41,42 
Inactivation of IL-2ry, which is shared by several cytokines (IL-2, IL-4, IL-7, IL-15 
and IL-21) crucial to T- and B-cell growth, allowed for much better multilineage 
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immune suppression and overcame the inherent “leakiness” observed in 
NOD/SCID mice, which eventually develop T- and B-cells with age.43 This 
mutation was also introduced into and (NOD)/Rag1/2null mice to generate NRG 
[(NOD)/Rag1/2null IL-2rynull)] mice, whose immune impairment is dependent on 
hematopoietic specific RAG deficiency, thus leaving DNA repair intact.  
Functionally these mice were a revolutionary leap in xenograft mouse 
models of human leukemia and show multiple immune deficiencies well beyond 
lymphocytic impairment. These mice exhibit defects in T, B, and natural killer 
(NK) cells as well as markedly reduced dendritic cell and macrophage function.41 
Extremely enhanced engraftment rates of human cell lines, HSCs, and even 
primary patient samples have been observed, as well as well-defined 
differentiation and maturation of multiple distinct hematopoietic lineages upon 
human HSC xenograft as compared to parent strains. Of particular importance 
was the finding that these mice support the differentiation and proliferation of 
human T-cells, specifically CD4 and CD8 single positive cells, which do not 
develop in NOD/SCID mice. Indeed these strains, particularly the NSG mouse, 
have become the workhorses for modeling and studying human leukemogenesis 
and hematopoiesis in an in vivo system that begins to attempt to mimic 
physiological conditions experienced by leukemic cells in the human body. Such 
in vivo systems that are capable of faithfully replicating physiological conditions, 
and support the proliferation of human or patient derived leukemia, are critical in 
the search for novel therapeutics that have a high potential of advancing to 
clinical trials and/or becoming approved therapies.          
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 While these mice provided a revolutionary leap in the study of both normal 
and leukemic human hematopoiesis, they fail to model several important 
conditions experienced by human AML patients. The most glaring and obvious 
disadvantage is the lack of a fully functional immune system, especially the 
lymphocytic compartment which is severely impaired to allow for the engraftment 
and proliferation of human cells. Attempts are now being made to develop mice 
with “humanized” immune systems, and essentially rely on transplantation of 
normal human CD34+ HSCs into competent immune compromised mice. Several 
groups have been able to show well characterized differentiation along multiple 
well defined hematopoietic lineages, and most importantly the presence of 
human T and B lymphocytes. Unfortunately the utility of these “humanized” 
mouse systems remain insufficient as the resulting human cells are often times 
not fully functional, and fail to produce immunomodulatory molecules like 
cytokines and IgG upon antigen presentation.44 Mouse models of human 
leukemia that can eventually incorporate a functional human immune system will 
be required for truly translational investigation of novel therapeutics, especially 
immune based therapies.                                                                
  Second, and perhaps as important, is the lack of hematopoietic cytokine 
signaling as most mouse cytokines do not cross react with human cells. This is a 
major shortcoming as cytokine production and signaling is known to be required 
for both normal human hematopoiesis and plays a role in leukemic progression 
and clinical outcome. Additionally, this signaling is required for reliable homing, 
engraftment, and proliferation of both normal human HSCs, and xenograft patient 
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samples which are notoriously difficult to engraft.45 To overcome this problem 
several groups have developed a series of NOG and NSG mice that express 
transgenes for a variety of human cytokines specifically geared to the desired 
area of research (e.g. hIL-2, hIL-3, hIL-6, hGM-CSF, etc.).41,46,47 This 
development further improved these models by allowing for the engraftment, 
differentiation, and development of patient derived leukemia or normal human 
HSC in a BM microenvironment, as well as limited human cytokine signaling. 
 Despite these advances NOG and NSG mice have major flaw that is often 
overlooked, and is a result of a mutation in the Prdkc gene used to generate the 
SCID phenotype. This gene and its enzyme product Prdck are required for not 
only V(D)J recombination of lymphocytes but also DNA damage repair. As such 
these mice are highly intolerant to chemotherapeutics, especially DNA damaging 
agents, as they are unable to repair any of the damage caused by the drugs. 
This poses a significant challenge as the standard of care induction therapy for 
AML uses doxorubicin (or other anthracyclines like daunorubicin or idarubicin) 
and cytarabine, both DNA damaging compounds. Doxorubicin intercalates DNA 
thereby preventing macromolecular biosynthesis and through stabilization of 
topoisomerase II promotes breaks in the DNA. Cytarabine or cytosine 
arabinoside interferes with DNA synthesis due to rapid conversion to a toxic and 
DNA damaging intermediate, when the cell is in the S phase and replicating 
DNA. Thus mice harboring SCID immune deficiencies are extremely intolerant to 
treatment with these drugs, even at subtoxic doses in other mouse strains, a 
critical flaw. Truly translational models must be able to closely mimic the patient 
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experience, as well as model the standard of care therapy not only as a more 
relevant control, but also to investigate innovative and/or combinatorial 
therapeutics. Taken together a more clinically and translationally relevant mouse 
model of AML will require not only mice capable of receiving and supporting 
human patient xenografts, but also express human myeloid cytokines and 
tolerate aggressive chemotherapeutic treatment similar to clinical induction 
therapy. 
 Recently, Mulloy et. Al. developed a new strain of mice by crossing NRG 
mice with NSGS mice which are essentially NSG mice that harbor the SGM3 
(3GS) triple coinjected transgenes that express human interleukin 3 (IL-3), 
granulocyte/macrophage colony stimulating factor (GM-CSF), and steel factor 
(SF). Upon genotyping of the offspring, selective breeding together or with NRG 
mice allowed for the removal of the SCID mutation resulting in NRGS mice which 
are essentially NRG mice that also express the SGM3 transgene. Thus these 
mice have no mature T cells, B cells, or NK cells due to the hematopoetic 
specific Rag mutation (as opposed to a SCID mutation) and express three 
human cytokines important for both engraftment and support of human myeloid 
cells. Since these mice do not depend on a SCID mutation to mediate immune 
suppression they have functional DNA repair and should be able to tolerate 
clinically comparable doses of chemotherapeutics and previous studies have 
shown that these mice maintain the radioresistance that is a hallmark of the NRG 
strain. This strain of mice is truly cutting edge in terms of modeling human 
hematopoiesis, both normal and malignant, as not only can these mice tolerate 
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aggressive  induction chemotherapy and dose escalation, but also express three 
human cytokines necessary for the engraftment and support of human myeloid 
cells.























We hypothesize that we can develop a more clinically relevant xenograft 
mouse model of human AML for the investigation of novel therapeutics and 
treatment paradigms. This is essential, especially for AML which is a uniquely 
heterogeneous cancer that presents with a variety of morphologies and express 
a diverse array of genetic and molecular irregularities, each with their own 
associated treatment sensitivities and clinical outcomes. Our model is hinged on 
NRGS mice which will not only allow for high rates of human AML cell 
engraftment, but will also attempt to recapitulate some human myeloid cytokine 
signaling. Finally, the model must be resilient enough to tolerate aggressive 
induction chemotherapy at doses similar to those experienced by AML patients, 
and treatment with induction chemotherapeutics must provide a significant 
survival outcome in mice engrafted with human AML. Establishment of such a 
model will be crucial to the discovery of novel compounds, whose efficacy 
against patient specific AML can be tested against and in combination with 
standard of care induction therapy. Compounds identified in this model system 
are expected to have considerably improved success rates in advancement to 





MATERIALS AND METHODS 
ANIMAL STUDIES 
NRGS mice were obtained from Jackson laboratories and bred and maintained at 
the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12-
hour dark cycle and provided food and water ad libitum. Animals were maintained 
under standard conditions and all animal procedures were approved by the 
Institutional Animal Care and Use Committee. In all studies the appropriate number 
of human AML cells from established lines, patient derived cells, or MYC/BCLXL 
induced murine leukemia were resuspended in PBS and tail vein injected at a final 
volume of 200 µl. Mice receiving “5+3” therapy were weighed daily and given a dose 
of 75 mg/kg of cytarabine for five days and 3 mg/kg doxorubicin for three days by 
bolus tail vein injection, with each injection being balanced with PBS such that each 
mouse receives a total volume of 200 µl. Mice in the vehicle groups received 
injections of 200 µl plain PBS for all five days. Upon development of leukemia or 
termination of the experiment mice were sacrificed and FACS analysis conducted on 
the spleen, thymus, and BM   
REAGENTS AND ANTIBODIES  
Clinical formulations of both doxorubicin and cytarabine were obtained from the 
James Graham Brown Cancer Center as single dose self-sealing vials containing 20 
mg/10 ml or 2g/20ml respectively, manufactured by APP a division of Fresenius Kabi 
USA LLC (Lake Zurich, IL).
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CELL CULTURE  
Cells were maintained in culture at 37° C under 5% CO2 in RPMI 1460 growth media 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. 
PATIENT SAMPLES 
Patient derived AML cells obtained from the spleen of an NSG mouse engrafted with 
the primary patient leukemia, were a generous gift from our collaborator Dr. James 
Mulloy, at Cincinnati Children’s Hospital.   
FACS ANALYSIS 
Both the spleen and BM were analyzed by FACS. In brief, single cells were isolated 
from tissues; red blood cells were lysed and blocked for 10 mins at room 
temperature with Fc Block (#553142 BD Biosciences, Miami, FL, USA). The 
samples were then stained with anti-human CD45 antibody conjugated to the Alexa 
700 fluorophore, from BioLegend (San Diego, CA) for 20 mins at 4° C and then 






Engraftment of multiple human AML cell lines in NRGS mice. First we wanted to 
examine the engraftment and subsequent disease progression of NRGS mice tail-
vein injected with 1 x 105 human AML cells. Differential rates of engraftment based 
on leukemic subtype and classification were examined by injecting either OCI-AML3 
cells or KG1 cells. Each of these cell lines represent dramatically different subtypes 
of AML and therefore the utility of this model for multiple cytogenetically distinct 
subtypes of AML encountered in the clinical setting. Three NRGS mice were injected 
with 1 x 105 of each cell line and monitored until humane endpoints were achieved. 
We found that both cell lines showed high rates of consistent engraftment (n=3) as 
quantified by the amount of detectable human CD45 in the spleen and BM by FACS. 
Mice injected with OCI-AML3 cells survived till approximately 30 days till human 
endpoints were reached, while mice injected with KG1 cells survived only 23-25 
days. This data corresponds to these cell lines in vitro growth rate as well as their 
subtype associated aggressiveness. These data indicated that NRGS mice are 
capable of high rates of engraftment and fairly rapid disease progression when 
injected with established human cell lines, allowing for the establishment of model 
systems that are capable of investigating novel therapeutics against various human 





Figure 1. Engraftment of 1 x 105 OCI-AML3 cells in NRGS mice. NRGS mice 
(n=3) were injected with 1 x 105 OCI-AML3 cells and maintained under standard 
conditions until humane endpoints were reached as characterized by distress, 
breathing difficulty, hind limb paralysis, etc. Mice had to be sacrificed from 30-32 
days after injection of cells and FACS analysis of the BM and spleen showed a large 
percentage of human cells (representative mouse shown). Approximately 30% of the 
cells in the spleen (A.) were human OCI-AML3 cells and surprisingly almost 50% of 
the BM. (B.) was comprised of human cells. The left column represents unstained 





Figure 2. Engraftment of 1 x 105 KG1 cells in NRGS mice. NRGS mice (n=3) 
were injected with 1 x 105 KG1 cells and maintained under standard conditions until 
humane endpoints were reached as characterized by distress, breathing difficulty, 
hind limb paralysis, etc. Mice had to be sacrificed after 23-25 days after injection of 
cells and FACS analysis of the BM and spleen showed a large percentage of human 
cells (representative mouse shown). Only 18% of the cells in the spleen were human 
KG1 cells and again almost 50% of the BM was comprised of human cells. Again the 
left hand column indicates analysis of unstained cells to account for any possible 
inherent auto fluorescence of the cells.         
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Engraftment of patient derived AML cells in NRGS mice. Once we were able to 
establish that high rates of engraftment and predictable disease progression could 
be achieved in our model using established human cells lines, we wanted to 
progress to the engraftment of notoriously difficult human patient derived AML cells. 
Previous studies have demonstrated that similar immune deficient mouse models of 
human AML can accurately predict patient chemotherapeutic response, and faithfully 
maintain the unique genetic and phenotypic identity of engrafted patient AML. We 
also wanted to confirm similar findings in our model, these findings being a 
prerequisite to a truly physiologically, translationally, and clinically relevant mouse 
model of AML. Therefore, the cells were examined by FACS analysis for human 
myeloid markers both pre-injection and post sacrifice. Thus, NRGS mice (n=5) were 
tail-vein injected with 1.25 x 105 patient derived AML cells (as determined by FACS 
analysis for human CD45) and maintained under standard conditions until visible 
signs of leukemia were evident and humane endpoints achieved. All mice had to be 
terminated at 41 days after injection of cells, and most mice showed overt signs of 
leukemia, like hind limb paralysis. FACS analysis of both the BM and the spleen 
showed the presence of a large percentage of human cells with the same myeloid 
antigen expression as compared to cells pre-injection, indicating that engraftment of 
the patient sample was successful. Interestingly both CD14 and CD33 are virtually 
undetectable upon defrost, but are heavily expressed after transplantation into the in 
vivo environment. These data indicate that NRGS mice are valuable tools that allow 
for the robust engraftment of both human cell lines, and more importantly primary 




Figure 3. FACS analysis of human myeloid cell surface markers upon defrost 
and before tail vein injection into NRGS recipients. After thawing the cells FACS 
analysis was conducted using antibodies against human CD45, CD33, CD11b, and 
CD14. Since these cells were acquired from the spleens of NSG mice transplanted 
with the primary patient leukemia approximately 41.7% of the cells were of human 
origin as characterized by human CD45 expression. The cells were positive only for 
huCD45 and huCD11b and showed no expression of huCD33, a common myeloid 
cell surface antigen, or huCD14 an antigen expressed by a variety of mature 









Figure 4. FACS analysis of human myeloid cell surface markers after injection 
and sacrifice of NRGS mice injected with 1.25 x 105 patient derived AML cells. 
After humane endpoints were achieved at 41 days, the mice were sacrificed and 
their hematopoetic organs were examined by FACS analysis to determine the 
percentage of human cells as well as examine the maintenance of cell surface 
marker expression. As expected there were a high percentage of human cells as 
identified by CD45 expression, and these cells maintained their human myeloid cell 
surface expression as compared to the patient cells upon defrost, with the exception 
of CD33 and CD14 which were detectable.          
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Treatment of leukemia in mice with a clinically similar dosing regimen of 
induction chemotherapeutics. As discussed in detail previously the current 
standard of care therapy for AML centers around administration of an anthracycline 
(doxorubicin, daunorubicin, idarubicn etc.) for three days combined with continuous 
infusion of cytarabine (Ara-C) for seven days and therefore often called “7+3”. Based 
on published studies from a collaborator, Dr. James Mulloy, we utilized his “5+3” 
regimen for mice which has been scaled down taking into account both body mass 
as well as differences in pharmacokinetics, but done using a different stain of mice. 
Therefore it was of crucial importance for us to investigate the efficacy of our 
treatment regimen in mice harboring leukemia, to be used as both a more relevant 
control and for investigation of combinatorial therapies. Thus, NRGS mice 
transplanted with patient AML cells were allowed to incubate for a week at which 
time they began daily tail vein injections of 75 mg/kg cytarabine for five days, and 
doxorubicin at 3 mg/kg for the first three days.   Recognizing a major criticism of 
these mouse models, including the lack of a functional immune compartment and 
the feasibility issues associated with the acquisition of primary patient samples, we 
also decided to test the efficacy of this same chemotherapeutic regimen on wild-type 
FVB mice engrafted with our own in house transplantable murine myeloid leukemia. 
This leukemia was generated by retroviral induced overexpression of Myc and 
BCLXL in normal BM hematopetic progenitors as previously described. This would 
provide an easier and more high-throughput methodology for screening novel 
therapeutics against and in combination with standard of care therapies, along with 
the influence of a fully functional immune compartment. Additionally, Myc is 
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recognized as one of the most potent oncogenes and BCLXL an extremely potent 
proliferative signal making this myeloid leukemia extremely aggressive. Therapies 
showing efficacy in this model will therefore have a high likelihood of success in 
clinical trials against patient leukemias which are generally much less aggressive. 
Here we show for the first time that “5+3” therapy with doxorubicin and cytarabine 
results in a significant enhancement of survival in both NRGS mice engrafted with 
patient derived AML cells and in FVB mice receiving our MYC/BCLxL induced 
murine myeloid leukemia. The survival benefit was much more pronounced in the 
NRGS mice with patient derived leukemia resulting in an average increase in 
survival of 12 days as compared to the vehicle treated mice. FVB mice engrafted 
with MYC/BCLxL induced myeloid leukemia show a diminished but still significant 
response to “5+3” induction therapy, with survival being prolonged by an average of 
7 days. Both these results indicate that NRGS mice are capable of handling 
aggressive chemotherapeutic treatment with standard of care therapy in a manner 
similar to the clinical experience of patients. Perhaps more importantly these data 
indicate that our treatment regimen is actually capable of treating both mice 
engrafted with patient derived leukemia and murine leukemia, a crucial finding, 








Figure 5. Treatment of NRGS mice engrafted with patient derived AML using 
“5+3” induction therapy. NRGS mice (n=10) were tail vein injected with 1.25 x 105 
patient derived AML cells obtained from the spleen of an NSG mouse engrafted with 
the primary patient leukemia and maintained under standard conditions for seven 
days. Next one group (n=5) was given “5+3” induction therapy composed of 3 mg/kg 
doxorubicin for the first three days and 75 mg/kg cytarabine all five days, while the 
vehicle group received sham injections of the vehicle PBS. Survival was significantly 
prolonged by an average of 12 days indicating that our clinically modeled regimen is 
effective in the treatment of patient derived leukemia, a crux in the development of a 
more clinically relevant AML mouse model that better recapitulates patient 
experience, and also as a control during the investigation of novel therapeutics. 
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Figure 6. Treatment of MYC/BCLXL induced murine myeloid leukemia in wild 
type FVB recipients with functional immune systems. FVB mice (n=10) were tail-
vein injected with 5 x 105 spleenocytes taken from an FVB mouse after development 
of MYC/BCLXL induced leukemia and sacrifice, and maintained under standard 
conditions for seven days. One group of mice (n=5) received “5+3” induction therapy 
with 75 mg/kg cytarabine administered all five days and 3 mg/kg doxorubicin for the 
first three days, while the vehicle group (n=5) received sham injections of PBS. 
Chemotherapeutic treatment significantly increased survival by an average of 7 
days, indicating that our dosing regimen is also effective against an extremely 
aggressive murine myeloid leukemia, albeit with decreased efficacy as compared to 
treatment of patient leukemia. Most importantly this model has a fully functional 
immune system allowing for more physiologically accurate investigation of 




Humanization of NRGS mice. The absolute pinnacle in the development of 
xenograft mouse models of patient AML would be the influence of a functional 
human immune system in addition to patient specific leukemia. Therefore we 
attempted to engraft sub-lethally irradiated NRGS mice (n=3) with human CD34+ 
multipotent HSCs obtained from umbilical cord blood, in the hope that we could 
observed multi-lineage expansion of human cells in the mouse microenvironment. 
Approximately 100 days after injection these mice were sacrificed and their spleens 
and BM analyzed by FACS analysis for the presence of several linage restricted 
human cell surface markers. Two of the three mice in this arm of the study showed 
the presence of human cells in the bone marrow, while all three mice showed no 
detectable human cells in the spleen. The mature human myeloid marker CD33 
could be detected at low levels in the BM (3.54%, 9.34%), and the human B-
lymphocyte antigen CD19 could be detected at higher levels (8.67%, 27.6%). Mouse 
#2 even stained positive for the human T-cell receptor CD3 at a detectable level 
(0.6%). These results demonstrate that NRGS mice are capable of being humanized 
upon sub-lethal irradiation and tail-vein injection of human CD34+ multipotent HSCs.  
The eventual goal of these studies is to incorporate a functional human immune 
system into our more clinically relevant patient xenograft AML mouse model, and 






Figure 7: FACS analysis of BM from sub-lethally irradiated NRGS mice 
engrafted with 5 x 105 human CD34+ HSCs. All three mice were sacrificed 
approximately 100 days post-injection of cells and their spleens and BM stained for 
the presence of huCD33, huCD19, and huCD3. Only the BM of two of the three mice 
stained positively and showed detectable expression of the three surface antigens. 
Mouse #1 showed 3.54% huCD33+, 8.67% huCD19+, and 0.059% huCD3+ cells in 
the bone marrow, while Mouse #2 had considerably higher engraftment with 9.34% 




 As previously emphasized acute myeloid leukemia displays a vast 
heterogeneity that is exquisitely unique to individual patients, and each case 
presents widely varied prognoses and drug sensitivities. Therefore investigation of 
novel therapeutic compounds and treatment strategies for AML that have a high 
likelihood of success in clinical trials require the development of truly translational 
mouse models, capable of recapitulating patient specific disease as well as standard 
of care therapy. Previous studies over the past 50 years have led to the 
development of immune deficient mouse models that are capable of supporting the 
growth and proliferation of both established human AML cell lines as well as primary 
patient samples, and these models have become widespread in the study of AML. 
However, several major hurdles remain in the development of a truly clinically 
relevant mouse models of AML namely the lack of human cytokine signaling, lack of 
a functional immune system, poor engraftment rates of primary patient samples, and 
finally the inability to tolerate clinically relevant doses of standard of care 
chemotherapy. Thus the focus of this study was to establish mouse models of AML 
pathogenesis that could overcome these issues, and more sound methodology for 
the investigation of novel therapeutics in a patient specific manner.
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 Our studies hinged on a newly developed strain of mice dubbed NRGS, which 
expresses three human cytokines and have functional DNA repair, and first we 
investigated the engraftment of established human AML cell lines (representing 
distinct subtypes) and subsequent leukemogenisis. Mice were tail vein injected with 
1x 106 OCI-AML3 or KG1 cells and similar to observed in vitro growth rates mice 
engrafted with OCI-AML3 cells developed leukemia and had to be sacrificed in 30-
32 days, while mice injected with KG1 cells had to sacrificed in only 23-25 days. All 
mice showed distinct signs of leukemic distress including hind limb paralysis as well 
as breathing difficulties, and necropsy revealed pronounced splenomegaly in all 
mice. This correlates with growth rates obseverved in vitro with KG1 cells showing a 
much faster growth rate and doubling time as compared to OCI-AML3 cells. Analysis 
of the spleen and BM showed the presence of human cells in both locations with 
approximately 50% of the cells in the BM identified as human cells, through human 
CD45 expression, upon injection of both cell lines. Interestingly OCI-AML3 cells 
were found at a much higher percentage in the spleen (approximately 30%) as 
compared to KG1 cells possibly indicating differential preference of location based 
on AML subtype. Finally both FACS analysis of surface markers and visual 
morphology of human cells isolated from the BM and/or the spleen confirmed the 
faithful maintenance of the human phenotype in the mouse microenvironment. 
These data indicate that NRGS mice allow for the reliable engraftment of human 
AML cells of varied subtype, and eventually develop fatal human leukemia 
detectable in the spleen and bone marrow. 
38 
 
 After confirming reliable rates of engraftment and consistent leukemic 
progression using established human cell lines we examined the engraftment of 
patient derived leukemia, obtained from the spleen of an NSG mouse after tail vein 
injection of primary patient AML and subsequent sacrifice upon development of 
leukemia. 1.25 x 105 patient AML cells were injected into NRGS mice and 41 days 
later a humane endpoint was achieved and all mice had to be sacrificed with most 
displaying either hind limb paralysis or breathing difficulties. This data indicates that 
NRGS mice show reliable rates of efficient sample engraftment as well as 
predictable disease progression, both essential to our model system. FACS analysis 
of human cells obtained upon sacrifice showed continued expression of CD45 and 
CD11b as compared to initial analysis of the cells upon thawing. However after 
exposure to the in vivo environment and possibly the human cytokines, patient cells 
harvested from leukemic NRGS mice showed a strong expression of both CD33 as 
well as CD14, both undetectable upon defrost or short term in vitro cell culture. 
These findings highlight the importance of not only the in vivo microenvironment, but 
also human cytokine signaling, and suggest that they are crucial to accurately 
maintain the patient specific AML phenotype. In future studies it will be critical to 
examine the engraftment of primary patient samples taken directly from the clinic as 
our cells were passaged once through an NSG mouse which may have resulted in 
selection for cells that were best adapted to the mouse microenvironment. The 
expression of human cytokines (IL-3, GM-CSF, and SF) is expected to greatly 
facilitate the implantation and engraftment of primary patient cells, but this remains 
to be investigated in our hands.   
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 Perhaps the most important goal of this study was to establish a clinically 
comparable and efficacious dosing regimen of induction therapy using doxorubicin 
and cytarabine. Based on the work of our collaborator Dr. Jim Mulloy, we tested a 
“5+3” induction therapy regimen composed of bolus tail vein injections of 3 mg/kg 
doxorubicin for the first three days and 75 mg/kg cytarabine for five days, which was 
shown to be well tolerated in NRG mice and comparable to clinically experienced 
doses of these drugs.48 Therapy using this dosing regimen was highly efficacious in 
the treatment of NRGS mice engrafted with our patient derived leukemia and 
resulted in a significant increase in average survival of 11.4 days. These data are 
crucial to our model system as we conclusively show that not only can NRGS mice 
be reliably engrafted with patient derived AML cells and develop leukemia, but also 
that our “5+3” induction therapy regimen is effective in treating patient derived 
leukemia and provides a significant survival advantage. Future studies will not only 
attempt to escalate the dose of induction therapeutics but also use this regimen as a 
more relevant control during the study of novel therapeutics, alone and/or as 
combinatorial therapy, against patient derived AML.  
 A major shortcoming not addressed by this model is the influence of a 
functional immunity on both leukemic progression and therapeutic efficacy of 
experimental therapeutics. In an attempt to test our “5+3” induction therapy regimen 
in a model with a functional immune system we injected 5 x 105 spleenocytes from a 
WT FVB mouse harboring our own in house murine AML, into sub-lethally irradiated 
WT FVB recipient mice and after a week these mice were put on our “5+3” regimen. 
This AML is generated by simultaneous retroviral overexpression of MYC and 
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BCLxL in normal WT FVB BM hematopoetic progenitors. MYC is widely recognized 
as one of the most potent oncogenes and BCLxL an extremely strong proliferative 
signal, and overexpression of both in hematopoetic progenitors result in an 
extremely aggressive and transplantable murine AML. Data obtained from this study 
clearly indicates that our model induction therapy regimen also provides a significant 
survival advantage to WT FVB mice transplanted with aggressive MYC/BClxL 
induced AML, and a fully functional immune system.  
 Additionally, we attempted to engraft sub-lethally irradiated NRGS mice with 
normal human CD34+ HSCs to determine if multilineage expansion of human 
immune cells was possible. While human cells of both the T- and B-lineage were 
detected in two of the three mice in the study, the rates of differentiation and 
expansion were generally poor. While disappointing, these results highlight the 
feasibility of developing NRGS mice with normal functional human immunity in 
conjunction with patient derived AML. It is likely that conditioning of the mice is 
required for the engraftment of human HSCs and their subsequent differentiation 
and expansion into immune cells.   
 Novel therapeutics and combinatorial therapies, especially immune based 
therapies, could be tested for efficacy alone and in combination with the standard of 
care therapy in such a model, and compounds that show efficacy in both models will 
most likely have a higher likelihood of success in clinical trials. The successful 
discovery of truly translational novel therapeutics for AML will hinge on the 
development and implementation of similar, more clinically relevant mouse models 
of patient specific AML that faithfully recapitulate the unique cytogenetic and 
41 
 
morphological profile of patient disease, the influence of the BM microenvironment, 
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